EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression

Adittya Arefin iD, Matthew C Gage iD

International Journal of Molecular Sciences · 01.03.2023 · 24 (5) · 4785

DOI: 10.3390/ijms24054785 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.03.2023. Verfasst von Adittya Arefin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Wolfson Institute for Biomedical Research, Division of Medicine, University College London, Gower Street, London WC1E 6BT, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Macrophages, Metformin. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Diabetes UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type-2 Diabetes Mellitus is a complex, chronic illness characterized by persistent high blood glucose levels. Patients can be prescribed anti-diabetes drugs as single agents or in combination depending on the severity of their condition. Metformin and empagliflozin are two commonly prescribed anti-diabetes drugs which reduce hyperglycemia, however their direct effects on macrophage inflammatory responses alone or in combination are unreported. Here, we show that metformin and empagliflozin elicit proinflammatory responses on mouse bone-marrow-derived macrophages with single agent challenge, which are modulated when added in combination. In silico docking experiments suggested that empagliflozin can interact with both TLR2 and DECTIN1 receptors, and we observed that both empagliflozin and metformin increase expression of Tlr2 and Clec7a. Thus, findings from this study suggest that metformin and empagliflozin as single agents or in combination can directly modulate inflammatory gene expression in macrophages and upregulate the expression of their receptors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsMacrophagesMetforminAnimalsMiceBlood GlucoseDrug Therapy, CombinationGene ExpressionHyperglycemiaToll-Like Receptor 2Benzhydryl CompoundsGlucosides

Stichwörter der Autor:innen

anti-diabetes drugscombinationsdiabetesempagliflozininflammationmacrophagemetformin

Substanzen

Blood GlucoseHypoglycemic AgentsMetforminToll-Like Receptor 2empagliflozinBenzhydryl CompoundsGlucosides

Autor:innen und Institutionen

  • Wolfson Institute for Biomedical Research, Division of Medicine, University College London, Gower Street, London WC1E 6BT, UK.
  • Department of Comparative Biomedical Sciences, Royal Veterinary College, 4 Royal College Street, London NW1 0TU, UK.

ORCID-Profile: Adittya Arefin, Matthew C Gage

Förderung

  • British Heart Foundation
  • Diabetes UK

Zitieren

APA

Arefin, A., & Gage, M. C. (2023). Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression. International Journal of Molecular Sciences, 24(5), 4785. https://doi.org/10.3390/ijms24054785

Vancouver

Arefin A, Gage MC. Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression. International Journal of Molecular Sciences. 2023;24(5):4785. doi:10.3390/ijms24054785

BibTeX
@article{Arefin2023,
  author = {Arefin, Adittya and Gage, Matthew C},
  title = {Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {5},
  pages = {4785},
  doi = {10.3390/ijms24054785}
}
Kostenlos starten →